


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-1.08%
+0.44%
-0.26%
-8.24%
-9.34%
PFE
Pfizer
$25.52
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive
PFE Price Performance
$25.21 (+1.23%)
$24.76 (+3.07%)
$25.07 (+1.79%)
$26.44 (-3.48%)
PFE overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings decline YoY

Reported a strong earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
PFE Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PFE Street Sentiment is bullish and have positive views on the near-term outlook
PFE has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
NVS
143.58
-0.53%
SNY
45.74
-1.82%
AZN
89.94
-4.75%
MRK
109.45
+0.57%
NVO
60.68
-2.65%
PFE
Pfizer
25.52
-0.51%
ED
Consolidated Edison
105.05
+1.19%
MRK
Merck Company
109.45
+0.57%
SIGI
Selective Insurance
81.35
-0.66%
ACIW
ACI Worldwide
42.39
-1.40%
What is PFE current stock price?
What are PFE stock strengths?
What is PFE Risk Level?
What is PFE market cap and volume?
What is PFE current Stock IQ?
Should I buy PFE stock right now?
Is PFE a Strong Buy right now?
What does a 'Strong Buy' rating mean for PFE?
What does a 'Strong Sell' rating mean for PFE?
What factors influence PFE's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-1.08%
+0.44%
-0.26%
-8.24%
-9.34%
PFE
Pfizer
Current Price
$25.52
Stock Insights
Strengths

Earnings are forecast to grow

Trading below its fair value

Upgraded on attractively valued

Investors confidence is positive
Linked to PFE
NVS
143.58
-0.53%
SNY
45.74
-1.82%
AZN
89.94
-4.75%
MRK
109.45
+0.57%
NVO
60.68
-2.65%
Recently Viewed
PFE
Pfizer
25.52
-0.51%
ED
Consolidated Edison
105.05
+1.19%
MRK
Merck Company
109.45
+0.57%
SIGI
Selective Insurance
81.35
-0.66%
ACIW
ACI Worldwide
42.39
-1.40%

PFE Price Performance
$25.21 (+1.23%)
$24.76 (+3.07%)
$25.07 (+1.79%)
$26.44 (-3.48%)
PFE Analysts Opinion
PFE Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Above analyst estimates

Earnings decline YoY

Reported a strong earnings

Revenue increase YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Trading below its fair value

Outperform the market
![]()
PFE Analysts opinion is positive but there was a setback from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
PFE Street Sentiment is bullish and have positive views on the near-term outlook
PFE has Low risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk

Average key support and resistance price levels
Jan 16, 2026
Initiate
Neutral
UBS
Jan 12, 2026
Initiate
Neutral
UBS
Dec 30, 2025
Reiterate
Buy
Scotiabank
Dec 22, 2025
Downgrade
Hold
Dec 17, 2025
Reiterate
Buy
Guggenheim
PFE Stock IQ
PFE Latest Analysis
Novavax Licenses Matrix-M Adjuvant To Pfizer For Upfront Payment Of $30 Mln . (RTTNews) - Novavax Inc. (NVAX) announced Tuesday that it has entered into a license agreement with Pfizer Inc. (PFE) for use of Novavaxs Matrix-M adjuvant. Under the terms of the agreement Pfizer will obtain a non-exclusive license for Matrix-M for use with Pfizers products
Tue Jan 20, 2026
Abcam joins the Innovative Health Initiative LIGAND-AI project to advance artificial intelligence (AI)-driven drug discovery through open science. Abcam has joined an industry-academic partnership led by the Structural Genomics Consortium and Pfizer to advance AI-driven drug discovery through open science a new public-private partnership with a budget of more than €60 million. Through this collaboration the Innovative Health Initiative Project LIGAND-AI will generate large high-quality protein–l
Tue Jan 20, 2026
Pfizer exits GSK majority-owned ViiV Healthcare. Shionogi raises stake.
Tue Jan 20, 2026
Pfizer (PFE) CEO Isnt Ready For A Fight With RFK Jr. Says Jim Cramer. We recently published 10 Stocks Jim Cramer Talked About. Pfizer Inc. (NYSE:PFE) is one of the stocks on Jim Cramer talked about. Pharma giant Pfizer Inc. (NYSE:PFE)s shares are down by 4.7% over the past year and flat year-to-date. UBS initiated coverage of the stock in January as it set a Neutral rating for the [….]
Fri Jan 16, 2026
Why Pfizer Inc. (PFE) is One of the Best Affordable Stocks Under $30. Pfizer Inc. (NYSE:PFE) is one of the best affordable stocks under $30. Pfizer Inc. (NYSE:PFE) announced on January 10 positive results from Cohort 3 which is a separate randomized cohort of the pivotal BREAKWATER trial evaluating BRAFTOVI® in combination with cetuximab and FOLFIRI in patients with previously untreated metastatic colorectal cancer with a BRAF V600E [….]
Thu Jan 15, 2026
PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock. Pfizer shares fall nearly 5% in a month after weak 2026 guidance sparking debate over buying the dip or staying cautious.
Wed Jan 14, 2026
Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra.
Mon Jan 12, 2026
UBS Likes Pfizers MTSR Obesity Deal but Stays Neutral on PFE. Pfizer Inc. (NYSE:PFE) is included among the 13 Best Dividend Stocks Paying Over 6%. On January 7 UBS initiated coverage of Pfizer Inc. (NYSE:PFE) with a Neutral rating and a $25 price target. The firm pointed to lingering uncertainty around Pfizers revenue outlook with roughly $15 billion to $20 billion tied to major drugs expected [….]
Mon Jan 12, 2026
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript.
Mon Jan 12, 2026
Pfizer inks licensing deal with Madrigal for MASH candidate.
Fri Jan 9, 2026
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.